HUSSAIN IQBAL J 4
4 · Centessa Pharmaceuticals plc · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Centessa (CNTA) Chief Legal Officer Hussain Iqbal Sells Shares, Receives RSUs
What Happened
Hussain Iqbal, Centessa Pharmaceuticals' Chief Legal Officer, sold a total of 47,741 Centessa shares in late Jan–early Feb 2026 for aggregate proceeds of about $1,196,073, and received 220,000 new equity awards (RSUs/options) the same period. Sales included open-market transactions and a disposition to cover tax/option exercise-related obligations; the awards consist of RSUs and a derivative option grant with a multi-month vesting schedule.
Key Details
- Transactions and amounts:
- 2026-01-30: Sold 1,010 shares at $25.01 — $25,261.
- 2026-02-01: 7,780 shares disposed at $24.57 to cover exercise price/tax — $191,155 (tax/withholding).
- 2026-02-02: Sold 38,951 shares at a weighted average $25.15 — $979,657. (Weighted-price ranges disclosed in filing.)
- 2026-02-02: Awarded 40,000 RSUs (no cash cost) — vesting in four equal annual installments beginning Feb 2, 2027.
- 2026-02-02: Awarded 20,000 RSUs (no cash cost) — vests on Feb 2, 2027.
- 2026-02-02: Awarded 160,000 derivative shares (option/award) — vests 1/48th monthly starting Mar 2, 2026.
- Total sold: 47,741 shares for ~$1.20M; total awards received: 220,000 shares (RSUs/options).
- Footnotes of interest:
- Some shares may be represented by American Depositary Shares (ADS) (each ADS currently = one Ordinary Share).
- Several sale prices are reported as weighted averages; the filing offers ranges and says the reporting person will provide per-price breakdown on request.
- 7,780-share disposition was to cover tax withholding related to vesting.
- Shares owned after the transactions: not specified in the data provided.
- Filing/timeliness: Filing date shown as Feb 3, 2026. No explicit late-filing indicator was provided in the supplied details.
Context
- These transactions combine routine sales (open-market) and company compensation (RSU/option grants). The 7,780-share disposition was a tax/withholding action (common when RSUs vest), while the larger awards are forward-looking compensation that vest over time — the 40k RSUs vest annually, the 20k RSUs vest on a single date, and the 160k option-style award vests monthly (1/48th).
- Sales do not necessarily indicate a change in sentiment; awards and vesting schedules can drive sales for tax or liquidity reasons. Purchases (not present here) tend to be more direct bullish signals.
Insider Transaction Report
Form 4
HUSSAIN IQBAL J
Chief Legal Officer
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-01-30$25.01/sh−1,010$25,261→ 104,376 total - Tax Payment
Ordinary Shares
[F1][F3]2026-02-01$24.57/sh−7,780$191,155→ 96,596 total - Sale
Ordinary Shares
[F1][F4]2026-02-02$25.15/sh−38,951$979,657→ 57,645 total - Award
Ordinary Shares
[F1][F5]2026-02-02+40,000→ 97,645 total - Award
Ordinary Shares
[F1][F6]2026-02-02+20,000→ 117,645 total - Award
Share Option (right to buy)
[F7][F1]2026-02-02+160,000→ 160,000 totalExercise: $25.19Exp: 2036-02-02→ Ordinary Shares (160,000 underlying)
Holdings
- 5,500(indirect: By Spouse)
Ordinary Shares
[F1]
Footnotes (7)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.
- [F6]The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest on February 2, 2027.
- [F7]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026.
Signature
/s/ Raphael Deferiere, attorney-in-fact|2026-02-03